Use of mycophenolate mofetil (MMF) in lupus nephritis (LN) in children by Indaco, R et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Pediatric Rheumatology
Open Access Poster presentation
Use of mycophenolate mofetil (MMF) in lupus nephritis (LN) in 
children
R Indaco*1, M Alessio1, MR Caropreso2, G Malgieri2 and C Pecoraro2
Address: 1Rheumatology Unit, Department of Pediatrics, Federico II University, Naples, Italy and 2Nephrology Unit, Department of Pediatrics, 
Santobono-Pausillipon Hospital, Naples, Italy
* Corresponding author    
Systemic lupus erythematosus (SLE) is a multisystemic
autoimmune disease; 86% of children with SLE have renal
involvement, that ranges from asymptomatic urinary
findings to nephritic syndrome and renal failure. Cyclo-
phosphamide (CYC) and corticosteroids (CCS) has been
the standard of care for many years, despite their failure or
potential toxicities. Studies have showed good results with
MMF in LN. We evaluated, in an observational study, the
efficacy of MMF as induction and maintenance therapy in
LN in children. Eighteen patients (15 female and 3 male,
median age 12,2 ys) were evaluated with biopsy-proven
LN, 13/18 received CYC or CCS as induction and then
MMF, 5/18 received MMF plus CCS as from start. The fol-
lowing parameters were recorded at baseline and follow-
up: serum creatinine, urinary protein excretion in 24
hours, full blood count, complement components (C3–
C4), ANA positivity, ENA profile, SLEDAI score and histo-
logic indices of activity and chronicity by Austin and coll.
The median treatment time with MMF was 3 years. Our
patients showed return in the range of normality of serum
creatinine (p < 0,01), urinary protein excretion in 24
hours (p < 0,01), full blood count, complement compo-
nents (C3–C4) (p < 0,01), ANA positivity (p < 0,01), ENA
profile (p < 0,01), SLEDAI score (p < 0,01) and histologic
indices of activity and chronicity (p < 0,01). In all patients
CCS was suspended in 2 months. We had only 2 patients
with adverse effects (1 diarrhoea, 1 viral infection). MMF
as induction and manteinance therapy can be efficacy and
safe in treatment of LN in children.
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